Vaxart Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vaxart stock.
View analyst ratings for Vaxart or view top-rated stocks.

Wall Street analysts have given Vaxart a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vaxart wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Vaxart.

Vaxart, Inc. (NASDAQ:VXRT) announced its earnings results on Sunday, May, 2nd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.04. The biotechnology company had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.62 million. Vaxart had a negative trailing twelve-month return on equity of 39.81% and a negative net margin of 2,844.24%. Vaxart's revenue was down 82.8% compared to the same quarter last year.
View Vaxart's earnings history.

Vaxart's stock was trading at $2.07 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VXRT stock has increased by 322.2% and is now trading at $8.74.
View which stocks have been most impacted by COVID-19.

Vaxart shares reverse split on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

3 Wall Street analysts have issued 1 year price targets for Vaxart's shares. Their forecasts range from $13.00 to $18.00. On average, they expect Vaxart's stock price to reach $16.00 in the next year. This suggests a possible upside of 83.1% from the stock's current price.
View analysts' price targets for Vaxart or view top-rated stocks among Wall Street analysts.

Some companies that are related to Vaxart include SpringWorks Therapeutics (SWTX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), Bavarian Nordic A/S (BVNRY), NanoString Technologies (NSTG), Vericel (VCEL), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Revolution Medicines (RVMD), Rubius Therapeutics (RUBY), bluebird bio (BLUE) and Kymera Therapeutics (KYMR).
View all of VXRT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxart investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novavax (NVAX), OrganiGram (OGI) and Novan (NOVN).

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Vaxart's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.59%), Geode Capital Management LLC (1.18%), Principal Financial Group Inc. (0.68%), Principal Financial Group Inc. (0.65%), Citigroup Inc. (0.50%) and Thrivent Financial for Lutherans (0.46%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Margaret Echerd, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart.

VXRT stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Credit Suisse AG, Barclays PLC, Morgan Stanley, Goldman Sachs Group Inc., Zurcher Kantonalbank Zurich Cantonalbank, Cubist Systematic Strategies LLC, and Pacer Advisors Inc.. Company insiders that have sold Vaxart company stock in the last year include Armistice Capital, Llc, Margaret Echerd, and Wouter Latour.
View insider buying and selling activity for Vaxart or view top insider-selling stocks.

VXRT stock was purchased by a variety of institutional investors in the last quarter, including Citigroup Inc., Thrivent Financial for Lutherans, BlackRock Inc., Rafferty Asset Management LLC, Geode Capital Management LLC, Millennium Management LLC, Squarepoint Ops LLC, and JPMorgan Chase & Co.. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, and Wouter Latour.
View insider buying and selling activity for Vaxart or or view top insider-buying stocks.

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VXRT stock can currently be purchased for approximately $8.74.

Vaxart has a market capitalization of $1.07 billion and generates $4.05 million in revenue each year. The biotechnology company earns $-32,220,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

Vaxart employs 28 workers across the globe.

The official website for Vaxart is www.vaxart.com.

Vaxart is headquartered at 290 Utah Ave. Suite 200, South San Francisco CA, 94080.

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at (650) 550-3500 or via email at [email protected]